Financial Survey: DENTSPLY SIRONA (XRAY) and NeuroMetrix (NURO)
DENTSPLY SIRONA (NASDAQ: XRAY) and NeuroMetrix (NASDAQ:NURO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
Insider & Institutional Ownership
94.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 6.5% of NeuroMetrix shares are owned by institutional investors. 2.0% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 4.4% of NeuroMetrix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings and recommmendations for DENTSPLY SIRONA and NeuroMetrix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DENTSPLY SIRONA currently has a consensus target price of $66.20, suggesting a potential upside of 18.92%. NeuroMetrix has a consensus target price of $26.00, suggesting a potential upside of 1,168.29%. Given NeuroMetrix’s stronger consensus rating and higher possible upside, analysts plainly believe NeuroMetrix is more favorable than DENTSPLY SIRONA.
DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. NeuroMetrix does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.
Valuation and Earnings
This table compares DENTSPLY SIRONA and NeuroMetrix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DENTSPLY SIRONA||$3.84 billion||3.33||$825.00 million||($3.47)||-16.04|
|NeuroMetrix||$15.72 million||0.28||-$13.27 million||($20.01)||-0.10|
DENTSPLY SIRONA has higher revenue and earnings than NeuroMetrix. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than NeuroMetrix, indicating that it is currently the more affordable of the two stocks.
This table compares DENTSPLY SIRONA and NeuroMetrix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
DENTSPLY SIRONA has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
DENTSPLY SIRONA beats NeuroMetrix on 12 of the 15 factors compared between the two stocks.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.
NeuroMetrix Company Profile
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.